Glioblastoma cells utilize evolutionarily adapted cell metabolism to promote their malignant proliferation.

Overview

1. Neuroscience Center, HiLIFE—Helsinki Institute of Life Science, University of Helsinki,Helsinki, Finland
2. Division of Microscopic Anatomy, Graduate School of Medical and Dental Sciences, Niigata University,Niigata, Japan
3. Translational Cancer Medicine Research Program, Faculty of Medicine, University of Helsinki,Helsinki, Finland
4. ICAN Digital Precision Medicine Flagship Program, University of Helsinki,Helsinki, Finland
5. Stem Cell and Metabolism Research Program, Faculty of Medicine, University of Helsinki,Helsinki, Finland
6. Laboratory Animal Center, HiLIFE—Helsinki Institute of Life Science, University of Helsinki,Helsinki, Finland
7. Department of Developmental Biology, Fujita Health University School of Medicine,Toyoake, Japan
8. Division of Developmental Neurobiology, International Center for Brain Science (ICBS), Fujita Health University,Toyoake, Japan

Abstract

Glioblastoma is the most aggressive primary brain tumor in adults, with limited therapeutic success and, therefore, poor prognosis. Its malignancy is partly driven by the high proliferative capacity of glioblastoma cells, yet the underlying molecular mechanisms remain unclear. Recent studies have revealed transcriptomic similarities between glioblastoma cells and human fetal neural stem/progenitor cells (NSCs), suggesting that glioblastoma may exploit developmental programs that promote NSC proliferation. Fetal human NSCs rely on glutaminolysis—a metabolic pathway induced by the human-specific mitochondrial protein ARHGAP11B—to sustain proliferation. Here, we show that ARHGAP11B expression correlates with glioma malignancy and is essential for glioblastoma cell proliferation, implicating a critical role of glutaminolysis in tumor growth. Among glutaminolysis-related enzymes, glutamic-oxaloacetic transaminase 2 (GOT2) shows a strong positive correlation with glioma grade and poor patient prognosis. Functional assays reveal that GOT2 knockdown significantly suppresses glioblastoma cell growth, indicating that GOT2-mediated glutaminolysis is critical for their proliferation. Metabolomic profiling further shows that GOT2 is required for nucleotide precursor synthesis, underscoring its role in supporting DNA replication. Consistently, GOT2 depletion reduces the proportion of glioblastoma cells in the S phase of the cell cycle. These findings suggest glioblastoma cells hijack an evolutionarily adapted metabolic program to support malignant growth.

Supplementary Information: The online version contains supplementary material available at 10.1186/s40478-026-02318-7.

Reproduced under the paper's license (CC BY), from the paper cited above.

Code

The paper links to its data, not to its authors' code: see the Data section.

Tracing map

A tracing map links a paper to the code its authors published: this paper has none, so it has no map.

Data

Datasets cited

• figshare:32944084, at figshare; found in DataCite

Other data links

• ncbi.nlm.nih.gov/geo, NCBI; found in the text, “Data analysis”

Data availability

All data are available in the manuscript or the supplementary material, or publicly available as indicated in the Materials and Methods. Glioblastoma cells are available upon reasonable request to PL. Other materials are available upon reasonable request to TN.

Reproduced under the paper's license (CC BY), from the paper cited above.

Versions

The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.

Version 1, 28 September 2026: the first record

Recorded: type, language, journal, volume, issue, pages, dates, 13 authors, 10 keywords, 7 MeSH terms, 1 funder, 64 references.

Cite

This paper

Bespalov, M. M., Gkini, V., Iloglu, Z., Yamada, S., Nemoto, A., Filppu, P., Trontti, K., Andriichuk, L., Pietiläinen, O., Le Joncour, V., Nieminen, A. I., Laakkonen, P., & Namba, T. (2026). Glioblastoma cells utilize evolutionarily adapted cell metabolism to promote their malignant proliferation. Acta neuropathologica communications, 14(1), 146. https://doi.org/10.1186/s40478-026-02318-7

Similar papers

The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.

[1] doi:10.1038/s42003-026-10802-y

Transcriptome of fetal cortex of tree shrew underlying the emergence of outer subventricular zone.

Journal: Communications biology

In common: 6 references

[2] doi:10.3390/cancers18132092

TGFB2 as a Prognostic Biomarker Associated with Myeloid-Enriched, Multi-Checkpoint-Activated Immunosuppression in Diffuse Glioma: A Multi-Cohort Transcriptomic Study.

Journal: Cancers

In common: other condition, 6 references

[3] doi:10.3390/ijms27167240

1-Piperidine Propionic Acid Inhibits PAR2/SerpinB3 Signaling and Reduces Glioblastoma Tumor Aggressiveness.

Journal: International journal of molecular sciences

In common: other condition, cellular / molecular, 5 references

[4] doi:10.1016/j.isci.2026.115982 [code]

Multi-omics profiling-derived signature links cellular ecosystem to glioblastoma prognosis.

Journal: iScience

In common: other condition, 4 references

[5] doi:10.1080/17501911.2026.2691031

Promoter methylation-associated brain-enriched long noncoding RNAs in glioblastoma: a multi-cohort public epigenomic re-analysis.

Journal: Epigenomics

In common: other condition, cellular / molecular, 4 references

[6] doi:10.32604/or.2026.079221

Single-Cell Sequencing Reveals the Heterogeneity of Glioma and Identifies IGFBP2 as A Potential Therapeutic Target.

Journal: Oncology research

In common: other condition, cellular / molecular, 4 references

[7] doi:10.1186/s12967-026-08266-z [code]

Single-cell multi-omic integration analysis prioritizes druggable genes and reveals cell-type-specific causal effects in glioblastomagenesis.

Journal: Journal of translational medicine

In common: other condition, cellular / molecular, 4 references

[8] doi:10.3390/cancers18162616

Decitabine Reprograms Temozolomide-Resistant Glioblastoma Through Epigenetic Reactivation and Mesenchymal Attenuation: A Multi-Omics Study.

Journal: Cancers

In common: other condition, 4 references

[9] doi:10.1016/j.cell.2026.05.026 [code]

The critical role of the endogenous immune compartment after CAR T cell therapy in recurrent GBM.

Journal: Cell

In common: other condition, 4 references

[10] doi:10.7554/elife.89001 [code]

Human-specific lncRNAs contributed critically to human evolution by distinctly regulating gene expression.

Journal: eLife

In common: cellular / molecular, 3 references

Contribute

The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.

Request its removal

To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).

Discussion: questions and error reports about this paper and its code, from signed-in readers and its authors. It opens with sign-in.

Reproductions: reports from readers who ran the authors' code: what they reproduced, with which environment, commit and data. It opens with sign-in.

Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.